Reustle, Anna
Di Marco, Moreno
Meyerhoff, Carolin
Nelde, Annika
Walz, Juliane S.
Winter, Stefan
Kandabarau, Siahei
Büttner, Florian
Haag, Mathias
Backert, Linus
Kowalewski, Daniel J.
Rausch, Steffen
Hennenlotter, Jörg
Stühler, Viktoria
Scharpf, Marcus
Fend, Falko
Stenzl, Arnulf
Rammensee, Hans-Georg
Bedke, Jens
Stevanović, Stefan
Schwab, Matthias
Schaeffeler, Elke
Funding for this research was provided by:
Robert Bosch Stiftung
Deutsche Forschungsgemeinschaft
ICEPHA Graduate School
Deutsche Forschungsgemeinschaft
Article History
Received: 23 October 2019
Accepted: 12 March 2020
First Online: 30 March 2020
Ethics approval and consent to participate
: Use of primary tumor tissue samples with ccRCC histology of patients treated at the Department of Urology, University Hospital Tuebingen, Germany, was approved by the ethics committee of the University of Tuebingen, and informed written consent was provided by each subject prior to surgical resection. The research conformed to the principles of the Helsinki Declaration.
: Not applicable
: JB: consultancies, honoraria, or study participation from Bayer, BMS, GSK, Immatics, Novartis, Pfizer, and Roche. AS: consultancies, honoraria, or study participation from Bayer, BMS, Immatics, Novartis, Pfizer, and Roche. HGR: shareholder of Immatics and CureVac, consultancy for Roche. The remaining authors declare that they have no competing interests.